Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Prediction of fulvestrant efficacy in patients with advanced breast cancer : retrospective-prospective evaluation of the predictive potential of a multigene expression assay. / Christensen, Troels Dreier; Buhl, Anna Sofie Kappel; Christensen, Ib Jarle; Buhl, Ida Kappel; Balslev, Eva; Knoop, Ann S; Danø, Hella; Glavicic, Vesna; Luczak, Adam; Langkjer, Sven Tyge; Linnet, Søren; Jakobsen, Erik Hugger; Bogovic, Jurij; Ejlertsen, Bent; Rasmussen, Annie; Hansen, Anker; Knudsen, Steen; Jensen, Peter Buhl; Nielsen, Dorte.

I: Breast Cancer, Bind 27, Nr. 2, 03.2020, s. 266-276.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Christensen, TD, Buhl, ASK, Christensen, IJ, Buhl, IK, Balslev, E, Knoop, AS, Danø, H, Glavicic, V, Luczak, A, Langkjer, ST, Linnet, S, Jakobsen, EH, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Jensen, PB & Nielsen, D 2020, 'Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay', Breast Cancer, bind 27, nr. 2, s. 266-276. https://doi.org/10.1007/s12282-019-01017-7

APA

Christensen, T. D., Buhl, A. S. K., Christensen, I. J., Buhl, I. K., Balslev, E., Knoop, A. S., Danø, H., Glavicic, V., Luczak, A., Langkjer, S. T., Linnet, S., Jakobsen, E. H., Bogovic, J., Ejlertsen, B., Rasmussen, A., Hansen, A., Knudsen, S., Jensen, P. B., & Nielsen, D. (2020). Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer, 27(2), 266-276. https://doi.org/10.1007/s12282-019-01017-7

CBE

Christensen TD, Buhl ASK, Christensen IJ, Buhl IK, Balslev E, Knoop AS, Danø H, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Jensen PB, Nielsen D. 2020. Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer. 27(2):266-276. https://doi.org/10.1007/s12282-019-01017-7

MLA

Vancouver

Author

Christensen, Troels Dreier ; Buhl, Anna Sofie Kappel ; Christensen, Ib Jarle ; Buhl, Ida Kappel ; Balslev, Eva ; Knoop, Ann S ; Danø, Hella ; Glavicic, Vesna ; Luczak, Adam ; Langkjer, Sven Tyge ; Linnet, Søren ; Jakobsen, Erik Hugger ; Bogovic, Jurij ; Ejlertsen, Bent ; Rasmussen, Annie ; Hansen, Anker ; Knudsen, Steen ; Jensen, Peter Buhl ; Nielsen, Dorte. / Prediction of fulvestrant efficacy in patients with advanced breast cancer : retrospective-prospective evaluation of the predictive potential of a multigene expression assay. I: Breast Cancer. 2020 ; Bind 27, Nr. 2. s. 266-276.

Bibtex

@article{52a8296b169b400089da23c00aea5b26,
title = "Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay",
abstract = "BACKGROUND: Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women. The drug response predictor (DRP), is a mathematical algorithm based on the expression of multiple genes in the tumour. The fulvestrant DRP algorithm has previously shown effect in BC. In this study, we investigated the DRP's potential in predicting fulvestrant benefit.METHOD: Among 695 patients with ABC prospectively included in a Danish Breast Cancer Cooperative Group (DBCG) cohort we retrospectively included 226 patients who received fulvestrant as monotherapy. The DRP result was based on mRNA extracted from tumour biopsies and analysed using Affymetrix array. Primary endpoint was time to progression (TTP).RESULTS: For patients who received fulvestrant in line one to four and were previously unexposed to adjuvant endocrine therapy, we identified a hazard ratio (HR) of 0.44 (90% confidence interval (90% CI) upper limit of 1.08, one sided p = 0.066) for a predicted positive vs negative outcome. A weaker association was seen when including patients exposed to adjuvant endocrine treatment or received fulvestrant in fifth or later lines. Exploratory analyses showed that the DRP was efficient when using recent biopsies for DRP estimate and among recently treated patients.CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy.",
keywords = "Advanced breast cancer, Biomarker, Fulvestrant, Messenger RNA, BIOMARKERS, TRIAL, THERAPY, DOUBLE-BLIND, COMBINATION, POSTMENOPAUSAL WOMEN, 500 MG, AMERICAN SOCIETY",
author = "Christensen, {Troels Dreier} and Buhl, {Anna Sofie Kappel} and Christensen, {Ib Jarle} and Buhl, {Ida Kappel} and Eva Balslev and Knoop, {Ann S} and Hella Dan{\o} and Vesna Glavicic and Adam Luczak and Langkjer, {Sven Tyge} and S{\o}ren Linnet and Jakobsen, {Erik Hugger} and Jurij Bogovic and Bent Ejlertsen and Annie Rasmussen and Anker Hansen and Steen Knudsen and Jensen, {Peter Buhl} and Dorte Nielsen",
year = "2020",
month = mar,
doi = "10.1007/s12282-019-01017-7",
language = "English",
volume = "27",
pages = "266--276",
journal = "NPJ Breast Cancer",
issn = "2374-4677",
publisher = "Springer Nature",
number = "2",

}

RIS

TY - JOUR

T1 - Prediction of fulvestrant efficacy in patients with advanced breast cancer

T2 - retrospective-prospective evaluation of the predictive potential of a multigene expression assay

AU - Christensen, Troels Dreier

AU - Buhl, Anna Sofie Kappel

AU - Christensen, Ib Jarle

AU - Buhl, Ida Kappel

AU - Balslev, Eva

AU - Knoop, Ann S

AU - Danø, Hella

AU - Glavicic, Vesna

AU - Luczak, Adam

AU - Langkjer, Sven Tyge

AU - Linnet, Søren

AU - Jakobsen, Erik Hugger

AU - Bogovic, Jurij

AU - Ejlertsen, Bent

AU - Rasmussen, Annie

AU - Hansen, Anker

AU - Knudsen, Steen

AU - Jensen, Peter Buhl

AU - Nielsen, Dorte

PY - 2020/3

Y1 - 2020/3

N2 - BACKGROUND: Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women. The drug response predictor (DRP), is a mathematical algorithm based on the expression of multiple genes in the tumour. The fulvestrant DRP algorithm has previously shown effect in BC. In this study, we investigated the DRP's potential in predicting fulvestrant benefit.METHOD: Among 695 patients with ABC prospectively included in a Danish Breast Cancer Cooperative Group (DBCG) cohort we retrospectively included 226 patients who received fulvestrant as monotherapy. The DRP result was based on mRNA extracted from tumour biopsies and analysed using Affymetrix array. Primary endpoint was time to progression (TTP).RESULTS: For patients who received fulvestrant in line one to four and were previously unexposed to adjuvant endocrine therapy, we identified a hazard ratio (HR) of 0.44 (90% confidence interval (90% CI) upper limit of 1.08, one sided p = 0.066) for a predicted positive vs negative outcome. A weaker association was seen when including patients exposed to adjuvant endocrine treatment or received fulvestrant in fifth or later lines. Exploratory analyses showed that the DRP was efficient when using recent biopsies for DRP estimate and among recently treated patients.CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy.

AB - BACKGROUND: Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women. The drug response predictor (DRP), is a mathematical algorithm based on the expression of multiple genes in the tumour. The fulvestrant DRP algorithm has previously shown effect in BC. In this study, we investigated the DRP's potential in predicting fulvestrant benefit.METHOD: Among 695 patients with ABC prospectively included in a Danish Breast Cancer Cooperative Group (DBCG) cohort we retrospectively included 226 patients who received fulvestrant as monotherapy. The DRP result was based on mRNA extracted from tumour biopsies and analysed using Affymetrix array. Primary endpoint was time to progression (TTP).RESULTS: For patients who received fulvestrant in line one to four and were previously unexposed to adjuvant endocrine therapy, we identified a hazard ratio (HR) of 0.44 (90% confidence interval (90% CI) upper limit of 1.08, one sided p = 0.066) for a predicted positive vs negative outcome. A weaker association was seen when including patients exposed to adjuvant endocrine treatment or received fulvestrant in fifth or later lines. Exploratory analyses showed that the DRP was efficient when using recent biopsies for DRP estimate and among recently treated patients.CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy.

KW - Advanced breast cancer

KW - Biomarker

KW - Fulvestrant

KW - Messenger RNA

KW - BIOMARKERS

KW - TRIAL

KW - THERAPY

KW - DOUBLE-BLIND

KW - COMBINATION

KW - POSTMENOPAUSAL WOMEN

KW - 500 MG

KW - AMERICAN SOCIETY

U2 - 10.1007/s12282-019-01017-7

DO - 10.1007/s12282-019-01017-7

M3 - Journal article

C2 - 31654283

VL - 27

SP - 266

EP - 276

JO - NPJ Breast Cancer

JF - NPJ Breast Cancer

SN - 2374-4677

IS - 2

ER -